Ticker LaunchReverse merger · Completed · PTHS
LNHC, Inc. (Ligand Pharmaceuticals subsidiary)
Reverse merger with Channel Therapeutics Corporation (CHRO)
LNHC, Inc. (Ligand Pharmaceuticals subsidiary) merged into Channel Therapeutics Corporation (CHRO), a clinical-stage biotech developing non-opioid pain therapeutics, in a reverse merger that takes the private company public. The deal was announced on Apr 16, 2025 and closed on Jul 1, 2025. The combined company trades as Pelthos Therapeutics Inc. (PTHS) on NYSE American.
- Status
- Completed
- Private company
- LNHC, Inc. (Ligand Pharmaceuticals subsidiary)
- Public company
- Channel Therapeutics Corporation (CHRO)
- Public company business before
- clinical-stage biotech developing non-opioid pain therapeutics
- Announced
- Apr 16, 2025
- Closed
- Jul 1, 2025
- Combined company
- Pelthos Therapeutics Inc. (PTHS)
- Exchange
- NYSE American
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Jul 2, 2025
- Closing press release
- Announcement 8-K Jul 29, 2024
- Announcement press release
- All filings on EDGAR CIK 1919246
Other completed reverse mergers
- Mechanics Bankinto HomeStreet, Inc. · Sep 2, 2025
- Rhino Digital Inc.into Phoenix Plus Corp. · Aug 19, 2025
- Nakamoto Holdings Inc.into Kindly MD, Inc. · Aug 14, 2025
- Inmagene Biopharmaceuticalsinto Ikena Oncology, Inc. · Jul 25, 2025
- Abundia Global Impact Group, LLCinto Houston American Energy Corp. · Jul 1, 2025
- Crescent Biopharma, Inc.into GlycoMimetics, Inc. · Jun 13, 2025